Abstract
Elevated maternal homocysteine (Hcys) is a well-established risk factor for embryonic toxicity and the development of congenital defects, particularly neural tube closure defects and neurocristopathies. The mechanisms responsible are unclear but early work has focused on the role of folate metabolism because these defects are greatly reduced by folate supplementation. As a consequence, elevated Hcys is often looked upon as being an indirect consequence of faulty folate metabolism, although more recent studies show Hcys may act directly as a teratogen. Because Hcys is at the crossroads of protein and DNA metabolism, has a propensity to chemically modify proteins directly, can generate free radicals, and even perturb ligand binding to certain receptors, the developmental processes Hcys can potentially disturb are enumerable. But in recent years, investigators have begun identifying cellular and molecular targets for the direct action of Hcys. While elevating Hcys can alter a myriad of basic cellular activities needed for normal development, our current understanding as to the specific etiological mechanisms responsible for congenital defects is very speculative. Here we provide an overview of what is currently known regarding the toxicity and teratogenicity of elevated Hcys during embryonic development, paying particular attention to neural tube and neural crest cell morphogenesis.
Keywords: homocysteine, folate, neural tube defects, neurocristopathies, congenital birth defects, neural crest, morphogenesis, teratogen, toxicity, embryo
Current Pharmaceutical Design
Title: Consequences of Elevated Homocysteine During Embryonic Development and Possible Modes of Action
Volume: 10 Issue: 22
Author(s): P. R. Brauer and B. J. Tierney
Affiliation:
Keywords: homocysteine, folate, neural tube defects, neurocristopathies, congenital birth defects, neural crest, morphogenesis, teratogen, toxicity, embryo
Abstract: Elevated maternal homocysteine (Hcys) is a well-established risk factor for embryonic toxicity and the development of congenital defects, particularly neural tube closure defects and neurocristopathies. The mechanisms responsible are unclear but early work has focused on the role of folate metabolism because these defects are greatly reduced by folate supplementation. As a consequence, elevated Hcys is often looked upon as being an indirect consequence of faulty folate metabolism, although more recent studies show Hcys may act directly as a teratogen. Because Hcys is at the crossroads of protein and DNA metabolism, has a propensity to chemically modify proteins directly, can generate free radicals, and even perturb ligand binding to certain receptors, the developmental processes Hcys can potentially disturb are enumerable. But in recent years, investigators have begun identifying cellular and molecular targets for the direct action of Hcys. While elevating Hcys can alter a myriad of basic cellular activities needed for normal development, our current understanding as to the specific etiological mechanisms responsible for congenital defects is very speculative. Here we provide an overview of what is currently known regarding the toxicity and teratogenicity of elevated Hcys during embryonic development, paying particular attention to neural tube and neural crest cell morphogenesis.
Export Options
About this article
Cite this article as:
Brauer R. P. and Tierney J. B., Consequences of Elevated Homocysteine During Embryonic Development and Possible Modes of Action, Current Pharmaceutical Design 2004; 10 (22) . https://dx.doi.org/10.2174/1381612043383692
DOI https://dx.doi.org/10.2174/1381612043383692 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardioprotective Effects of Natural Products <i>via</i> the Nrf2 Signaling Pathway
Current Vascular Pharmacology Peripartum Cardiomyopathy: Moving Towards a More Central Role of Genetics
Current Cardiology Reviews Adverse Effects of Statins - Myths and Reality
Current Pharmaceutical Design Alterations in the Vascular Reactivity of Aorta in the Early and Late Phase of Adjuvant-Induced Arthritis in Rat
Vascular Disease Prevention (Discontinued) C6-Ceramide-Coated Catheters Promote Re-Endothelialization of Stretch- Injured Arteries
Vascular Disease Prevention (Discontinued) The Effects of Statin Therapy on the Human Airway
Drug Metabolism Letters Epidemiology of NHP-Drug Interactions: Identification and Evaluation
Current Drug Metabolism New Technologies in Male Contraception
Current Women`s Health Reviews Cannabinoid Modulation of Perivascular Sympathetic and Sensory Neurotransmission
Current Vascular Pharmacology Patents on Therapeutic and Cosmetic Applications of Bioactives of Crocus Sativus L. and their Production through Synthetic Biology Methods: A Review
Recent Patents on Biotechnology Intrinsic Disorder in Male Sex Determination: Disorderedness of Proteins from the Sry Transcriptional Network
Current Protein & Peptide Science Inflammation and Coronary Artery Disease
Current Vascular Pharmacology Evaluation of the Biological Fate and the Transport Through Biological Barriers of Nanosilver in Mice
Current Pharmaceutical Design Medical Treatment of Primary, Secondary, and Tertiary Hyperparathyroidism
Current Drug Safety The Effects of Prostaglandin E-1 in Patients with Intermittent Claudication
Cardiovascular & Hematological Disorders-Drug Targets The Role of Statins for the Primary and Secondary Prevention of Coronary Heart Disease in Women
Current Pharmaceutical Design Why Do We Need New Gene Therapy Viral Vectors? Characteristics, Limitations and Future Perspectives of Viral Vector Transduction
Current Gene Therapy Fatty Aspirin: A New Perspective in the Prevention of Dementia of Alzheimers Type?
Current Alzheimer Research Hypertension in Peripheral Arterial Disease
Current Pharmaceutical Design Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors
Current Pharmaceutical Design